|
1
|
Wong WM, Poulsom R and Wright NA: Trefoil
peptides. Gut. 44:890–895. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoffmann W and Jagla W: Cell type specific
expression of secretory TFF peptides: colocalization with mucins
and synthesis in the brain. Int Rev Cytol. 213:147–181. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taupin D and Podolsky DK: Trefoil factors:
initiators of mucosal healing. Nat Rev Mol Cell Biol. 4:721–732.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thim L: Trefoil peptides: from structure
to function. Cell Mol Life Sci. 53:888–903. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masiakowski P, Breathnach R, Bloch J,
Gannon F, Krust A and Chambon P: Cloning of cDNA sequences of
hormone-regulated genes from the MCF-7 human breast cancer cell
line. Nucleic Acids Res. 10:7895–7903. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rio MC, Bellocq JP, Daniel JY, et al:
Breast cancer-associated pS2 protein: synthesis and secretion by
normal stomach mucosa. Science. 241:705–708. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tomasetto C, Masson R, Linares JL,
Wendling C, Lefebvre O, Chenard MP and Rio MC: pS2/TFF1 interacts
directly with the VWFC cysteine-rich domains of mucins.
Gastroenterology. 118:70–80. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoffmann W, Jagla W and Wiede A: Molecular
medicine of TFF-peptides: from gut to brain. Histol Histopathol.
16:319–334. 2001.PubMed/NCBI
|
|
9
|
Lefebvre O, Chenard MP, Masson R, et al:
Gastric mucosa abnormalities and tumorigenesis in mice lacking the
pS2 trefoil protein. Science. 274:259–262. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Colombel M, Dante R, Bouvier R, Ribieras
S, Pangaud C, Marechal JM and Lasne Y: Differential RNA expression
of the pS2 gene in the human benign and malignant prostatic tissue.
J Urol. 162:927–930. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buache E, Etique N, Alpy F, et al:
Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of
human breast cancer cells and mammary tumor development in
TFF1-knockout mice. Oncogene. 30:3261–3273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arumugam T, Brandt W, Ramachandran V, et
al: Trefoil factor 1 stimulates both pancreatic cancer and stellate
cells and increases metastasis. Pancreas. 40:815–822. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McChesney PA, Aiyar SE, Lee OJ, Zaika A,
Moskaluk C, Li R and El-Rifai W: Cofactor of BRCA1: a novel
transcription factor regulator in upper gastrointestinal
adenocarcinomas. Cancer Res. 66:1346–1353. 2006. View Article : Google Scholar
|
|
14
|
Milne AN, Carvalho R, Morsink FM, Musler
AR, de Leng WW, Ristimäki A and Offerhaus GJ: Early-onset gastric
cancers have a different molecular expression profile than
conventional gastric cancers. Mod Pathol. 19:564–572. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gött P, Beck S, Machado JC, Carneiro F,
Schmitt H and Blin N: Human trefoil peptides: genomic structure in
21q22.3 and coordinated expression. Eur J Hum Genet. 4:308–315.
1996.PubMed/NCBI
|
|
16
|
Beck S, Sommer P, Blin N and Gött P:
5′-flanking motifs control cell-specific expression of trefoil
factor genes (TFF). Int J Mol Med. 2:353–361. 1998.
|
|
17
|
Al-azzeh ED, Fegert P, Blin N and Gött P:
Transcription factor GATA-6 activates expression of
gastroprotective trefoil genes TFF1 and TFF2. Biochim Biophys Acta.
1490:324–332. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beck S, Sommer P, dos Santos Silva E, Blin
N and Gött P: Hepatocyte nuclear factor 3 (winged helix domain)
activates trefoil factor gene TFF1 through a binding motif adjacent
to the TATAA box. DNA Cell Biol. 18:157–164. 1999. View Article : Google Scholar
|
|
19
|
Hernández C, Santamatilde E, McCreath KJ,
et al: Induction of trefoil factor (TFF) 1, TFF2 and TFF3 by
hypoxia is mediated by hypoxia inducible factor-1: implications for
gastric mucosal healing. Br J Pharmacol. 156:262–272.
2009.PubMed/NCBI
|
|
20
|
Japanese Gastric Cancer Association:
Japanese classification of gastric carcinoma: 3rd English ed.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar
|
|
21
|
Yanagihara K, Ito A, Toge T and Numoto M:
Antiproliferative effects of isoflavones on human cancer cell lines
established from the gastrointestinal tract. Cancer Res.
53:5815–5821. 1993.PubMed/NCBI
|
|
22
|
Yanagihara K, Tanaka H, Takigahira M, et
al: Establishment of two cell lines from human gastric scirrhous
carcinoma that possess the potential to metastasize spontaneously
in nude mice. Cancer Sci. 95:575–582. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakamura J, Kitajima Y, Kai K, et al:
Expression of hypoxic marker CA IX is regulated by site-specific
DNA methylation and is associated with the histology of gastric
cancer. Am J Pathol. 178:515–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Babyatsky MW, deBeaumont M, Thim L and
Podolsky DK: Oral trefoil peptides protect against ethanol- and
indomethacin-induced gastric injury in rats. Gastroenterology.
110:489–497. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Playford RJ, Marchbank T, Goodlad RA,
Chinery RA, Poulsom R and Hanby AM: Transgenic mice that
overexpress the human trefoil peptide pS2 have an increased
resistance to intestinal damage. Proc Natl Acad Sci USA.
93:2137–2142. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Peterson DE, Barker NP, Akhmadullina LI,
et al: Phase II, randomized, double-blind, placebo-controlled study
of recombinant human intestinal trefoil factor oral spray for
prevention of oral mucositis in patients with colorectal cancer who
are receiving fluorouracil-based chemotherapy. J Clin Oncol.
27:4333–4338. 2009. View Article : Google Scholar
|
|
27
|
Park WS, Oh RR, Park JY, et al: Mapping of
a new target region of allelic loss at 21q22 in primary gastric
cancers. Cancer Lett. 159:15–21. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park WS, Oh RR, Park JY, et al: Somatic
mutations of the trefoil factor family 1 gene in gastric cancer.
Gastroenterology. 119:691–698. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carvalho R, Kayademir T, Soares P, et al:
Loss of heterozygosity and promoter methylation, but not mutation,
may underlie loss of TFF1 in gastric carcinoma. Lab Invest.
82:1319–1326. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Beckler AD, Roche JK, Harper JC, et al:
Decreased abundance of trefoil factor 1 transcript in the majority
of gastric carcinomas. Cancer. 98:2184–2191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yio X, Diamond M, Zhang JY, Weinstein H,
Wang LH, Werther L and Itzkowitz S: Trefoil factor family-1
mutations enhance gastric cancer cell invasion through distinct
signaling pathways. Gastroenterology. 130:1696–1706. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lifton RP, Goldberg ML, Karp RW and
Hogness DS: The organization of the histone genes in Drosophila
melanogaster: functional and evolutionary implications. Cold
Spring Harb Symp Quant Biol. 42:1047–1051. 1978.
|
|
33
|
Semenza GL, Jiang BH, Leung SW, Passantino
R, Concordet JP, Maire P and Giallongo A: Hypoxia response elements
in the aldolase A, enolase 1, and lactate dehydrogenase A gene
promoters contain essential binding sites for hypoxia-inducible
factor 1. J Biol Chem. 271:32529–32537. 1996. View Article : Google Scholar
|
